Skip to content
Clinical Evidence
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
DETOUR System Reimbursement
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Procedural Training
For Patients
About Us
About Us
News
The Team
Careers
External Jobs
Internal Jobs
Investigator Initiated
Research
Contact Us
Clinical Evidence
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
DETOUR System Reimbursement
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Procedural Training
For Patients
About Us
About Us
News
The Team
Careers
External Jobs
Internal Jobs
Investigator Initiated
Research
Contact Us
Search
Back to News
December 19, 2016
Endologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft System
Prev
Previous
Positive Two-Year Data from the Nellix® EVAS FORWARD Global Registry Presented at 2016 VEITH Symposium
Next
Endologix Announces Temporary Hold on AFX to Resolve a Manufacturing Issue
Next
